US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

264.26

+2.410.92%

Post-market: 264.260.00000.00%16:10 EDT

Volume:26.18K

Turnover:6.90M

Market Cap:2.87B

PE:30.92

High:265.06

Open:264.46

Low:261.85

Close:261.85

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.80

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.03

PE(LYR):7.00

Loading ...

Overview Company News Filings

Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms

Simply Wall St.

Corcept Therapeutics CFO Atabak Mokari Disposes of 40,000 Common Shares for $3.52 Million

Can Veracyte (VCYT) Stay Reasonable After A 145% Rally?

Simply Wall St.

Bruker Nano President Mark Munch Sells 2,000 Bruker Shares Worth $120,500

Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma

Neo Performance Materials Inc (NEO) Gets a Buy from Stifel Nicolaus

Ernexa Therapeutics announces new ERNA-101 preclinical data

Bruker Acquires Noscendo’s Disqver Metagenomic Sequencing Platform

Bruker Corp - Disqver Acquisition not Expected to be Material to Bruker FY26 Results

THOMSON REUTERS

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic Mngs Disqver® Platform for Pathogenic Microorganisms in Blood

THOMSON REUTERS

Bruker Corp: Financial Details of Transaction were not Disclosed

THOMSON REUTERS

Bruker Corp : TD Cowen Raises Target Price to $60 from $45

THOMSON REUTERS

Veracyte Inc : Piper Sandler Initiates Coverage with Overweight Rating; Price Target $66

THOMSON REUTERS

Alkermes Schedules Second-quarter Results Call and Webcast

Alkermes to Report Second Quarter Financial Results on July 28, 2026

THOMSON REUTERS

Veracyte is Maintained at Hold by Canaccord Genuity

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?

Simply Wall St.

Voyager Therapeutics advances tau-silencing gene therapy program

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/FBT/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":264.26,"timestamp":1789416000000,"preClose":261.85,"halted":0,"volume":26178,"hourTrading":{"tag":"盘后","latestPrice":264.26,"preClose":264.26,"latestTime":"16:10 EDT","volume":10,"amount":2640.46,"timestamp":1789416604379,"change":0,"changeRate":0,"amplitude":0.008099},"delay":0,"changeRate":0.009203742600725484,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Post-Mkt","change":2.41,"latestTime":"09-14 16:13:00 EDT","open":264.46,"high":265.055,"low":261.845,"amount":6904236.5053199995,"amplitude":0.012259,"askPrice":266.74,"askSize":200,"bidPrice":261.61,"bidSize":200,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":261.85,"sharesOutstanding":11450002,"nav":262.39,"aum":2860051524.78,"bidAskSpread":0.001026,"postHourTrading":{"tag":"盘后","latestPrice":264.26,"preClose":264.26,"latestTime":"16:10 EDT","volume":10,"amount":2640.46,"timestamp":1789416604379,"change":0,"changeRate":0,"amplitude":0.008099},"volumeRatio":0.797993,"impliedVol":0.214,"impliedVolPercentile":0.5458},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.797993,"shares":10850002,"dividePrice":0,"high":265.055,"amplitude":0.012259,"preClose":261.85,"low":261.845,"week52Low":173.975,"pbRate":"1.03","psRate":"691.69","week52High":274.99,"institutionHeld":0,"latestPrice":264.26,"eps":8.545272,"divideRate":0,"volume":26178,"delay":0,"ttmEps":8.545272,"open":264.46,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":270.93,"twentyDayClose":255.42,"sixtyDayClose":227.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652345692","title":"Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2652345692","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652345692?lang=en_us&edition=fundamental","pubTime":"2026-07-18 19:24","pubTimestamp":1784373847,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics has delivered very strong long term share price gains over the past five years, yet its latest valuation checks lean more cautious, leaving investors weighing a powerful performance track record against a weak overall value score.\n\nCorcept Therapeutics is up about 346.1% over five years, which puts the recent share price in the context of a very strong run already behind it.\nProgress with cortisol modulating drugs, including Lifyorli and the resubmitted relacorilant...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-trade-at-a-discount-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-trade-at-a-discount-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1559883803.SGD","FBT","PSCH","TSPA","LU0566484027.USD","BK4007","BK4532","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652233480","title":"Corcept Therapeutics CFO Atabak Mokari Disposes of 40,000 Common Shares for $3.52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2652233480","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652233480?lang=en_us&edition=fundamental","pubTime":"2026-07-18 06:32","pubTimestamp":1784327541,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics CFO Atabak Mokari disposes of 40,000 common shares for $3.52 millionCorcept Therapeutics CFO Atabak Mokari exercised stock options on July 15, 2026, acquiring 40,000 common shares","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL4tTLkC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics CFO Atabak Mokari Disposes of 40,000 Common Shares for $3.52 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","LU1559883803.SGD","BK4532","CORT","FBT","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652786214","title":"Can Veracyte (VCYT) Stay Reasonable After A 145% Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652786214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652786214?lang=en_us&edition=fundamental","pubTime":"2026-07-17 06:34","pubTimestamp":1784241286,"startTime":"0","endTime":"0","summary":"Veracyte’s share price has climbed sharply over the past year, yet the valuation checks are pulling in different directions. An intrinsic value estimate based on a Discounted Cash Flow (DCF) suggests the stock trades below that estimate, while market multiples lean expensive and the broader score is weak.\n\nVeracyte has returned 144.5% over the past year, which puts extra focus on whether recent gains already reflect the company’s prospects.\nRising earnings estimates and growth plans in areas...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/can-veracyte-vcyt-stay-reasonable-after-a-145-rally","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/can-veracyte-vcyt-stay-reasonable-after-a-145-rally","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","FBT","BK4139","VGFPF","FEBU","VCYT","DECU","GXDW","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652424061","title":"Bruker Nano President Mark Munch Sells 2,000 Bruker Shares Worth $120,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2652424061","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652424061?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:15","pubTimestamp":1784232946,"startTime":"0","endTime":"0","summary":"Bruker Nano President Mark Munch sells 2,000 Bruker shares worth $120,500Bruker Nano Executive VP and President Mark Munch exercised stock options for 2,000 shares at USD 22.19 on July 15, 2026.Munch ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL96mhtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bruker Nano President Mark Munch Sells 2,000 Bruker Shares Worth $120,500","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU1815336091.USD","TINY","LU0757428866.USD","FBT","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652425738","title":"Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2652425738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652425738?lang=en_us&edition=fundamental","pubTime":"2026-07-17 00:31","pubTimestamp":1784219512,"startTime":"0","endTime":"0","summary":"Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The long term follow up study of AAVAnc80-antiVEGF gene therapy a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lilly-backed-gene-therapy-study-tracks-long-term-safety-in-vestibular-schwannoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lilly-backed-gene-therapy-study-tracks-long-term-safety-in-vestibular-schwannoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","CNCR","IBBQ","LFSC","FBT","BK4585","IBB","GNOM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410274","title":"Neo Performance Materials Inc (NEO) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651410274?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:16","pubTimestamp":1784204211,"startTime":"0","endTime":"0","summary":"In a report released today, Ian Gillies from Stifel Nicolaus maintained a Buy rating on Neo Performance Materials Inc, with a price target of C$49....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neo-performance-materials-inc-neo-gets-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neo-performance-materials-inc-neo-gets-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","UYM","NEO","LU0012050646.USD","BK4196","LU0106261612.USD","FBT","BK4127","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646874","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646874?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:15","pubTimestamp":1784117721,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","ERNA","FBT","BK4585","BK4588","SYNB","CNCR","IBBQ","BK4139","IBB","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651747452","title":"Bruker Acquires Noscendo’s Disqver Metagenomic Sequencing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2651747452","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651747452?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:01","pubTimestamp":1784113262,"startTime":"0","endTime":"0","summary":"Bruker acquires Noscendo’s DISQVER metagenomic sequencing platformBruker acquired the DISQVER clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio.DISQVE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDLhPZ2l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","TINY","FBT","BK4121","LU1815336091.USD","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651645222","title":"Bruker Corp - Disqver Acquisition not Expected to be Material to Bruker FY26 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2651645222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651645222?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:00","pubTimestamp":1784113201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA9YPR6T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU1815336091.USD","TINY","LU0757428866.USD","BK4121","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452278","title":"Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic Mngs Disqver® Platform for Pathogenic Microorganisms in Blood","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651452278?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:00","pubTimestamp":1784113201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA9YPR6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0757428866.USD","BRKR","TINY","FBT","BK4121","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651045222","title":"Bruker Corp: Financial Details of Transaction were not Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2651045222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651045222?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:00","pubTimestamp":1784113201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA9YPR6T:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TINY","LU1815336091.USD","LU0757428866.USD","FBT","BRKR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651518034","title":"Bruker Corp : TD Cowen Raises Target Price to $60 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2651518034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651518034?lang=en_us&edition=fundamental","pubTime":"2026-07-15 17:57","pubTimestamp":1784109461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0SS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU1815336091.USD","TINY","LU0757428866.USD","BK4121","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651458340","title":"Veracyte Inc : Piper Sandler Initiates Coverage with Overweight Rating; Price Target $66","url":"https://stock-news.laohu8.com/highlight/detail?id=2651458340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651458340?lang=en_us&edition=fundamental","pubTime":"2026-07-15 15:44","pubTimestamp":1784101462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651948609","title":"Alkermes Schedules Second-quarter Results Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2651948609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651948609?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:00","pubTimestamp":1784059224,"startTime":"0","endTime":"0","summary":"Alkermes schedules second-quarter results call and webcastAlkermes schedules a conference call and webcast at 8 a.m. ET on July 28, 2026 to discuss second-quarter financial results.Webcast player and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL4ZHnfJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","PSCH","MEDX","PSIL","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651248620","title":"Alkermes to Report Second Quarter Financial Results on July 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651248620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651248620?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:00","pubTimestamp":1784059200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA9LS4JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","IBRN","BK4139","PSCH","FBT","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651034451","title":"Veracyte is Maintained at Hold by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2651034451","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651034451?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:13","pubTimestamp":1784031180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VCYT/analyst-ratings(END) Dow Jones NewswiresJuly 14, 2026 08:13 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430120","title":"Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430120?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:29","pubTimestamp":1784010575,"startTime":"0","endTime":"0","summary":"In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib), with testing available across its national oncology laboratory network.\nThis test not only extends NeoGenomics’ presence into urologic oncology but also deepens its role in personalized prostate cancer care through rapid,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4092","LU0012050646.USD","NEO","BK4121","LU0106261612.USD","BK4196","PTEN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145087","title":"Voyager Therapeutics advances tau-silencing gene therapy program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145087?lang=en_us&edition=fundamental","pubTime":"2026-07-14 01:27","pubTimestamp":1783963636,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory prac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","VYGR","BK4585","GNOM","IBB","SYNB","LFSC","BK4139","FBT","CNCR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651143954","title":"Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651143954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651143954?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:10","pubTimestamp":1783959019,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBRN","ALKS","LU2324357040.USD","PRAX","LU0029874061.USD","IE00BJT1NW94.SGD","LABU","TMDX","HCSG","BK4585","BK4139","FBT","IE0002141913.USD","IE0009355771.USD","LU2065731478.USD","PSIL","BK4137","IE00BJJMRZ35.SGD","XLV","XBI","IE00B4R5TH58.HKD","LU0109394709.USD","MEDX","LU0889565916.HKD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","PSCH","BK4581","LU0128526141.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651128211","title":"Alkermes Plc : TD Cowen Raises Target Price to $57 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2651128211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651128211?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:29","pubTimestamp":1783949398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","IBRN","BK4139","ALKS","FBT","PSCH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}